BioPharmSignal logoBioPharmSignal

Biotech News

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences (HRMY)Harmony BiosciencesEarnings

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 23, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets.

Open original release

Related news

HRMYHarmony Biosciences2026-05-07 11:30 EST

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

NBIXNeurocrine Biosciences2026-05-05 20:01 EST

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-04-14 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

ABOSAcumen Pharmaceuticals2026-05-05 20:00 EST

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

XERSXeris Pharmaceuticals2026-04-23 11:30 EST

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

ALKSAlkermes plc2026-04-21 20:05 EST

Alkermes to Report First Quarter Financial Results on May 5, 2026

AXSMAxsome2026-04-08 11:00 EST

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

View all latest news

Harmony Biosciences

Harmony Biosciences is a sleep-disorders company built around narcolepsy and adjacent neurologic conditions.

Recent company news

HRMYHarmony Biosciences2026-05-07 11:30 EST

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

HRMYHarmony Biosciences2026-04-23 12:05 EST

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

HRMYHarmony Biosciences2026-04-16 12:05 EST

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

HRMYHarmony Biosciences2026-04-14 12:05 EST

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

HRMYHarmony Biosciences2026-04-02 12:05 EST

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Stock data

Close
36.01 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States